Humacyte, Inc.
General ticker "HUMA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $329.7M (TTM average)
Humacyte, Inc. does not follow the US Stock Market performance with the rate: -10.1%.
Estimated limits based on current volatility of 4.2%: low 1.08$, high 1.17$
Factors to consider:
- Total employees count: 185 (+12.8%) as of 2023
- Top business risk factors: Operational and conduct risks, Clinical trial success, Regulatory and compliance, Manufacturing scale up, Manufacturing risks
- Current price 61.9% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [3.12$, 7.63$]
- 2025-12-31 to 2026-12-31 estimated range: [2.86$, 7.09$]
Financial Metrics affecting the HUMA estimates:
- Positive: with PPE of -4.3 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -18.19 <= 0.01
- Negative: negative Net income
- Negative: Shareholder equity ratio, % of -38.20 <= 19.40
- Positive: Interest expense per share per price, % of 1.72 <= 3.28
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Investing cash flow per share per price, % of -0.29 > -0.63
Short-term HUMA quotes
Long-term HUMA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $1.56MM | $0.00MM | $0.00MM |
| Operating Expenses | $86.14MM | $100.05MM | $114.40MM |
| Operating Income | $-84.58MM | $-100.05MM | $-114.40MM |
| Non-Operating Income | $72.61MM | $-10.73MM | $-34.30MM |
| Interest Expense | $6.20MM | $6.60MM | $9.28MM |
| R&D Expense | $63.26MM | $76.55MM | $88.60MM |
| Income(Loss) | $-11.96MM | $-110.78MM | $-148.70MM |
| Profit(Loss)* | $-11.96MM | $-110.78MM | $-148.70MM |
| Stockholders Equity | $116.93MM | $13.55MM | $-52.67MM |
| Assets | $204.30MM | $128.22MM | $137.87MM |
| Operating Cash Flow | $-71.13MM | $-73.31MM | $-98.12MM |
| Capital expenditure | $1.05MM | $2.28MM | $1.57MM |
| Investing Cash Flow | $4.84MM | $-0.17MM | $-1.57MM |
| Financing Cash Flow | $-1.45MM | $4.51MM | $114.18MM |
| Earnings Per Share** | $-0.12 | $-1.07 | $-1.26 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.